News
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...
The World Health Organisation (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...
Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...
As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...
11h
TheHealthSite on MSNWhat Is Lenacapavir? All About WHO Recommended Biannual HIV Prevention DrugA breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...
Foster City-headquartered Gilead Sciences Inc, a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced that the US FDA has approved ...
(RTTNews) - Gilead Sciences Inc. (GILD) announced that the U.S. Food and Drug Administration has approved Yeztugo (lenacapavir)-the company's injectable HIV-1 capsid inhibitor-as pre-exposure ...
Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval More than 100 people in the US were diagnosed with HIV every day in 2023 Gilead Sciences’ twice-yearly injectable pre-exposure ...
The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.
The FDA has approved Gilead Sciences’ Yeztugo (lenacapavir) as the first and only twice-yearly injectable option for HIV pre-exposure prophylaxis (PrEP) in adults and adolescents weighing at least 77 ...
HIV Drug: The U.S. FDA has approved Gilead Sciences' Yeztugo, a twice-yearly injection for HIV prevention, aiming to change the landscape of HIV care. This revolutionary treatment costs $28,218 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results